LUTATHERA® Funded in Ontario

Radiopharmaceutical cancer treatment Lutathera® now available to Ontario patients with midgut neuroendocrine tumours (NETs). The Ontario funding criteria covers the treatment of adult patients with somatostatin receptor-positive (SSR+) midgut NETs [...]

By |2020-10-10T14:14:05-04:00October 10th, 2020|Treatment News|Comments Off on LUTATHERA® Funded in Ontario

LUTATHERA® Funded in Quebec

As of September 30, 2020, the Québec Ministry of Health and Social Services has listed Lutathera on the Liste de Médicaments – Établissements. Lutathera will be reimbursed for GEP-NETs patients [...]

By |2020-10-03T15:46:51-04:00October 3rd, 2020|Treatment News|Comments Off on LUTATHERA® Funded in Quebec
Go to Top